OncoStem

Omics Related Diagnosis

CanAssist Breast developed by OncoStem, is a prognostic tool that helps in managing early-stage, hormone receptor-positive breast cancer. It evaluates multiple biomarkers in a tumor sample to calculate a risk score, which indicates the likelihood of cancer recurrence within five years post-surgery. This personalized approach aids oncologists in tailoring treatment plans, potentially sparing low-risk patients from unnecessary aggressive treatments and their side effects, while ensuring high-risk patients receive the care they need. CanAssist Breast represents a significant advancement in personalized breast cancer care, aiming to optimize treatment decisions and improve patient outcomes.

Overview
People

PRODUCTS

CanAssist Breast Test: This is their primary product, a prognostic test to assess the risk of breast cancer recurrence within five years post-surgery. It analyzes multiple biomarkers in the tumor tissue, offering a detailed risk score to guide personalized treatment plans

SERVICES

Personalized Risk Assessment, Diagnostic Laboratory Services, Consultation and Support

KEY PERSONAL

Manjiri Bakre

OncoStem Diagnostics Private Limited

Vikram Srinivasan

OncoStem

KEYWORDS

Oncostem Diagnostics, Cancer diagnostics solutions, Personalized cancer risk assessment, Prognostic tests, Cancer risk evaluation, Cancer screening, Cancer detection, Oncology diagnostics, Precision medicine in cancer, Molecular diagnostics, Cancer treatment planning, Cancer biomarkers, Breast cancer risk assessment, Cancer prevention, Cancer risk management